Acid-Resistant Mesoporous Metal-Organic Framework toward Oral Insulin Delivery: Protein Encapsulation, Protection, and Release

Yijing Chen; Peng Li; Justin A. Modica; Riki J. Drout; Omar K. Farha

doi:10.1021/jacs.8b02089

Acid-Resistant Mesoporous Metal-Organic Framework toward Oral Insulin Delivery: Protein Encapsulation, Protection, and Release

Yijing Chen, Peng Li, Justin A. Modica, Riki J. Drout, Omar K. Farha^*

^*Corresponding author for this work

Chemistry

Research output: Contribution to journal › Article › peer-review

263 Scopus citations

Abstract

Diabetes affects millions of people worldwide and the number of diagnoses continues to climb annually. Though several effective medications and therapeutic methods have been developed to treat type 1 (T1DM) and type 2 (T2DM) diabetes mellitus, direct insulin injection remains the only effective treatment for insulin resistant (IR) diabetes patients. Here, we immobilize insulin in a crystalline mesoporous metal-organic framework (MOF), NU-1000, and obtain a high loading of ∼40 wt % in only 30 min. The acid-stable MOF capsules are found to effectively prevent insulin from degrading in the presence of stomach acid and the digestive enzyme, pepsin. Furthermore, the encapsulated insulin can be released from NU-1000 under simulated physiological conditions.

Original language	English (US)
Pages (from-to)	5678-5681
Number of pages	4
Journal	Journal of the American Chemical Society
Volume	140
Issue number	17
DOIs	https://doi.org/10.1021/jacs.8b02089
State	Published - May 2 2018

ASJC Scopus subject areas

Catalysis
Chemistry(all)
Biochemistry
Colloid and Surface Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/jacs.8b02089

Cite this

@article{842e03a6c526458bb17f0e59c3600a81,

title = "Acid-Resistant Mesoporous Metal-Organic Framework toward Oral Insulin Delivery: Protein Encapsulation, Protection, and Release",

abstract = "Diabetes affects millions of people worldwide and the number of diagnoses continues to climb annually. Though several effective medications and therapeutic methods have been developed to treat type 1 (T1DM) and type 2 (T2DM) diabetes mellitus, direct insulin injection remains the only effective treatment for insulin resistant (IR) diabetes patients. Here, we immobilize insulin in a crystalline mesoporous metal-organic framework (MOF), NU-1000, and obtain a high loading of ∼40 wt % in only 30 min. The acid-stable MOF capsules are found to effectively prevent insulin from degrading in the presence of stomach acid and the digestive enzyme, pepsin. Furthermore, the encapsulated insulin can be released from NU-1000 under simulated physiological conditions.",

author = "Yijing Chen and Peng Li and Modica, {Justin A.} and Drout, {Riki J.} and Farha, {Omar K.}",

year = "2018",

month = may,

day = "2",

doi = "10.1021/jacs.8b02089",

language = "English (US)",

volume = "140",

pages = "5678--5681",

journal = "Journal of the American Chemical Society",

issn = "0002-7863",

publisher = "American Chemical Society",

number = "17",

}

TY - JOUR

T1 - Acid-Resistant Mesoporous Metal-Organic Framework toward Oral Insulin Delivery

T2 - Protein Encapsulation, Protection, and Release

AU - Chen, Yijing

AU - Li, Peng

AU - Modica, Justin A.

AU - Drout, Riki J.

AU - Farha, Omar K.

PY - 2018/5/2

Y1 - 2018/5/2

N2 - Diabetes affects millions of people worldwide and the number of diagnoses continues to climb annually. Though several effective medications and therapeutic methods have been developed to treat type 1 (T1DM) and type 2 (T2DM) diabetes mellitus, direct insulin injection remains the only effective treatment for insulin resistant (IR) diabetes patients. Here, we immobilize insulin in a crystalline mesoporous metal-organic framework (MOF), NU-1000, and obtain a high loading of ∼40 wt % in only 30 min. The acid-stable MOF capsules are found to effectively prevent insulin from degrading in the presence of stomach acid and the digestive enzyme, pepsin. Furthermore, the encapsulated insulin can be released from NU-1000 under simulated physiological conditions.

AB - Diabetes affects millions of people worldwide and the number of diagnoses continues to climb annually. Though several effective medications and therapeutic methods have been developed to treat type 1 (T1DM) and type 2 (T2DM) diabetes mellitus, direct insulin injection remains the only effective treatment for insulin resistant (IR) diabetes patients. Here, we immobilize insulin in a crystalline mesoporous metal-organic framework (MOF), NU-1000, and obtain a high loading of ∼40 wt % in only 30 min. The acid-stable MOF capsules are found to effectively prevent insulin from degrading in the presence of stomach acid and the digestive enzyme, pepsin. Furthermore, the encapsulated insulin can be released from NU-1000 under simulated physiological conditions.

UR - http://www.scopus.com/inward/record.url?scp=85046344271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046344271&partnerID=8YFLogxK

U2 - 10.1021/jacs.8b02089

DO - 10.1021/jacs.8b02089

M3 - Article

C2 - 29641892

AN - SCOPUS:85046344271

VL - 140

SP - 5678

EP - 5681

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 17

ER -

Acid-Resistant Mesoporous Metal-Organic Framework toward Oral Insulin Delivery: Protein Encapsulation, Protection, and Release

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this